BFM
RCKT icon

Boothbay Fund Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Boothbay Fund Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Sell
94,727
-11,672
-11% -$38.8K ﹤0.01% 1704
2026
Q1 		$381K Buy
106,399
+14,757
+16% +$58.6K ﹤0.01% 1502
2025
Q4 		$322K Sell
91,642
-7,099
-7% -$24.3K ﹤0.01% 1387
2025
Q3 		$322K Buy
+98,741
New +$311K ﹤0.01% 1412
2025
Q2 		– Sell
-50,270
Closed -$335K – 1719
2025
Q1 		$335K Sell
50,270
-1,860
-4% -$18.4K 0.01% 1019
2024
Q4 		$655K Buy
52,130
+8,894
+21% +$134K 0.02% 784
2024
Q3 		$799K Hold
43,236
– – 0.02% 820
2024
Q2 		$931K Sell
43,236
-21,936
-34% -$504K 0.02% 745
2024
Q1 		$1.76M Buy
65,172
+16,891
+35% +$480K 0.03% 551
2023
Q4 		$1.45M Sell
48,281
-83,911
-63% -$1.85M 0.04% 597
2023
Q3 		$2.71M Buy
+132,192
New +$2.4M 0.06% 401
2018
Q2 		– Sell
-19,032
Closed -$360K – 868
2018
Q1 		$357K Buy
+19,032
New +$310K 0.04% 411
2017
Q4 		– Sell
-34,933
Closed -$249K – 800
2017
Q3 		$249K Buy
34,933
+16,922
+94% +$77.3K 0.04% 439
2017
Q2 		$137K Sell
18,011
-6,098
-25% -$45.5K 0.03% 595
2017
Q1 		$193K Buy
+24,109
New +$162K 0.04% 610

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boothbay Fund Management's RCKT Position: Q2 2026 in Review

Boothbay Fund Management reduced its Rocket Pharmaceuticals (RCKT) stake by 11% in Q2 2026, selling an estimated $38.8K and leaving 94,727 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #1704.

Boothbay Fund Management first reported a position in RCKT in Q1 2017 and has held it in 15 quarters since. The position peaked at $2.71M in Q3 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Boothbay Fund Management held 94,727 shares of Rocket Pharmaceuticals worth $324K as of Q2 2026.
  • Boothbay Fund Management sold 11,672 Rocket Pharmaceuticals shares in Q2 2026, an estimated $38.8K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1704 holding.
  • Boothbay Fund Management first reported a position in Rocket Pharmaceuticals in Q1 2017 and has held it in 15 quarters since.
  • Boothbay Fund Management's Rocket Pharmaceuticals position peaked at $2.71M in Q3 2023.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.